Lapatinib, an oral dual ErbB1/2 tyrosine kinase inhibitor, is effective in the treatment of metastatic breast cancer that has progressed after trastuzumab-based first-line chemotherapy. Moreover, lapatinib has been found to be effective in patients with metastatic brain involvement. Here we report the case of a 55-year-old woman with metastatic breast cancer and brain metastasis who achieved rapid symptom improvement and long-term disease control.
GeyerC.E., ForsterJ., LindquistD., ChanS., Gilles RomieuC., PienkowskiT., Jagiello-GruszfeldA., CrownJ., ChanA., KaufmanB., SkarlosD., CamponeM., DavidsonN., BergerM., OlivaC., RubinS.D., SteinS., CameronD.: Lapatinib plus capecitbanine for Her2-positive advanced breast cancer. N Engl J Med, 355: 2733–2743, 2006.
3.
CameronD., CaseyM., PressM., LindquistD., PienkowskiT., RomieuC.G., ChanS., Jagiello-GruszfeldA., KaufmanB., CrownJ., ChanA., CamponeM., ViensP., DavidsonN., GorbounovaV., RaatsJ.I., SkarlosD., NewstatB., RoychowdhuryD., PaolettiP., OlivaC., RubinS., SteinS., GeyerC.E.: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 112: 533–543, 2008.
4.
MoreiraC., KaklamaniV.: Lapatinib and breast cancer: current indications and outlook for the future. Expert Rev Anticancer Ther, 10: 1171–1182, 2010.
5.
KodackD.P., ChungE., YamashitaH., IncioJ., DuyvermanA.M., SongY., FarrarC.T., HuangY., AgerE., KamounW., GoelS., SnuderlM., LussiezA., HiddinghL., MahmoodS., TannousB.A., EichlerA.F., FukumuraD., EngelmanJ.A., JainR.K.: Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U SA, 109: E3119–E3127, 2012.
6.
BachelotT., RomieuG., CamponeM., DierasV., CropetC., DalencF., JimenezM., Le RhunE., PiergaJ.Y., GoncalvesA., LeherurteurM., DomontJ., GutierrezM., CurèH., FerreroJ.M., Labbe-DevilliersC.: Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol, 14: 64–71, 2013.
7.
LinN.U., CareyL.A., LiuM.C., YoungerJ., ComeS.E., EwendM., HarrisG.J., BullittE., Van den AbbeeleA.D., HensonJ.W., LiX., GelmanR., BursteinH.J., KasparianE., KirschD.G., CrawfordA., HochbergF., WinerE.P.: Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol, 26: 1993–1999, 2008.
